BIOMAT Database Logo BIOMAT Database Logo

Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. 1997

S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Department of Urology, Tokyo Medical and Dental University School of Medicine, Japan.

Serum levels of LH, FSH and testosterone (T) were measured by radioimmunoassays in 36 patients with advanced prostate cancer before and during androgen ablation therapies. Both leuprolide acetate (LH-RH agonist: LHRH-A) and diethylstilbestrol diphosphate (DES-DP) administration decreased serum LH significantly to an undetectable level (LHRH-A: P < 0.01, DES-DP: P < 0.05). LHRH-A and DES-DP diminished serum FSH to 20% of the pre-treatment level (P < 0.005) and to an undetectable level (P < 0.001), respectively. LHRH-A and DES-DP decreased serum T to the castration level and an undetectable level, respectively (P < 0.001). Serum levels of the same 3 hormones before and after DES-DP administration were measured in 8 patients who received DES-DP after LHRH-A treatment or castration because of relapse of the disease. DES-DP lowered serum FSH further than LHRH-A to an undetectable level (P < 0.005) and diminished T further than previous treatments to an undetectable level (P < 0.05 vs. LHRH-A, P < 0.01 vs. castration). These results suggest that 1) DES-DP is able to reduce T production from extra-testicular site(s), and achieve the minimal serum T level, and 2) this DES-DP action appears to be one of the mechanisms of the effectiveness of the estrogen on refractory prostate cancer after castration or LHRH-A. In addition, basal (independent of LH-RH) FSH secretion in elderly men is about 20% of total FSH secretion and DES-DP inhibits the basal FSH secretion at the level of the pituitary.

UI MeSH Term Description Entries
D008297 Male Males
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011966 Receptors, LHRH Receptors with a 6-kDa protein on the surfaces of cells that secrete LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE, usually in the adenohypophysis. LUTEINIZING HORMONE-RELEASING HORMONE binds to these receptors, is endocytosed with the receptor and, in the cell, triggers the release of LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE by the cell. These receptors are also found in rat gonads. INHIBINS prevent the binding of GnRH to its receptors. GnRH Receptors,Gonadoliberin Receptors,Gonadorelin Receptors,Gonadotropin Releasing-Hormone Receptors,LHFSHRH Receptors,LHRH Receptors,Luliberin Receptors,Receptors, GnRH,Receptors, Gonadoliberin,Receptors, Gonadorelin,Receptors, Luliberin,Follicle Stimulating Hormone-Releasing Hormone Receptors,GnRH Receptor,Gonadorelin Receptor,Gonadotropin-Releasing Hormone Receptor,LHRH Receptor,Luteinizing Hormone Releasing Hormone Receptors,Luteinizing Hormone Releasing-Hormone Receptor,Receptor, LHRH,Receptors, Gonadotropin Releasing-Hormone,Receptors, LHFSHRH,Follicle Stimulating Hormone Releasing Hormone Receptors,Gonadotropin Releasing Hormone Receptor,Gonadotropin Releasing Hormone Receptors,Hormone Receptor, Gonadotropin-Releasing,Luteinizing Hormone Releasing Hormone Receptor,Receptor, GnRH,Receptor, Gonadorelin,Receptor, Gonadotropin-Releasing Hormone,Receptors, Gonadotropin Releasing Hormone,Releasing-Hormone Receptors, Gonadotropin
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Effect of synthetic LH-RH on serum LH and FSH levels in patients with second grade amenorrhea.
July 1973, Acta obstetrica et gynaecologica Japonica,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Plasma testosterone, serum FSH, and serum LH levels in transvestism.
January 1979, Archives of sexual behavior,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
3 H-labelling of a synthetic decapeptide having LH and FSH releasing activity (LH-RH--FSH-RH).
October 1972, FEBS letters,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
[Male hormone--blood LH, FSH, and testosterone levels and LH-RH and HCG loading tests].
June 1979, Nihon rinsho. Japanese journal of clinical medicine,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
[Fluctuation of serum LH and FSH levels during administration of synthetic LH-RH in various types of ovarian dysfunction].
January 1976, Horumon to rinsho. Clinical endocrinology,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Serum levels of FSH, LH and testosterone in human males.
November 1974, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Further studies on the effects of testosterone on hypothalamic LH-RH and serum LH levels: castration-induced delayed response.
September 1985, Neuroendocrinology,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Serum LH, FSH and testosterone response to the administration of a new LH-RH analog, D-Trp6-LH-RH, in normal men.
January 1977, International journal of fertility,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Serum LH levels in bulls treated with synthetic luteinizing hormone-releasing hormone-follicle stimulating hormone-releasing hormone (LH-RH-FSH-RH).
July 1973, Journal of animal science,
S Kitahara, and K Yoshida, and K Ishizaka, and Y Kageyama, and S Kawakami, and T Tsujii, and H Oshima
Synthetic LH-RH stimulation monitored by immunochemical assay for urinary FSH and LH.
July 1974, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!